News Releases
This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
01 17 2024 Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024...
-
01 17 2024 Companies Collaborate to Broaden Access to Moleculera's Novel Neuropsychiatric Autoantibody TestingMoleculera Labs, Inc, a precision medicine company pioneering immune-mediated neuropsychiatric testing, today announced a strategic collaboration with Quest Diagnostics (DGX: NYSE), the nation’s...
01 09 2024 Goal to combine Ultima’s highly sensitive, low-cost technology with Quest’s oncology expertise and national scale in order to improve patient access, affordability and outcomes FREMONT, Calif...
-
01 08 2024 Transaction to broaden access to innovative, quality diagnostic information services for providers and patients SECAUCUS, N.J., Jan. 8, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the...
-
01 08 2024 Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology's personalized MRD...